Literature DB >> 27541366

Human pancreatic cancer progression: an anarchy among CCN-siblings.

Sushanta K Banerjee1,2,3,4, Gargi Maity5,6, Inamul Haque5,7, Arnab Ghosh5,7, Sandipto Sarkar5,8, Vijayalaxmi Gupta5,7, Donald R Campbell9, Daniel Von Hoff10, Snigdha Banerjee11,12.   

Abstract

Decades of basic and translational studies have identified the mechanisms by which pancreatic cancer cells use molecular pathways to hijack the normal homeostasis of the pancreas, promoting pancreatic cancer initiation, progression, and metastasis, as well as drug resistance. These molecular pathways were explored to develop targeted therapies to prevent or cure this fatal disease. Regrettably, the studies found that majority of the molecular events that dictate carcinogenic growth in the pancreas are non-actionable (potential non-responder groups of targeted therapy). In this review we discuss exciting discoveries on CCN-siblings that reveal how CCN-family members contribute to the different aspects of the development of pancreatic cancer with special emphasis on therapy.

Entities:  

Keywords:  CCN1; CCN2; CCN3; CCN4; CCN5; Genetically engineered mice model; Pancreatic cancer; Patient derived xenograft

Year:  2016        PMID: 27541366      PMCID: PMC5055500          DOI: 10.1007/s12079-016-0343-9

Source DB:  PubMed          Journal:  J Cell Commun Signal        ISSN: 1873-9601            Impact factor:   5.782


  121 in total

1.  Tumor uptake and elimination of 2',2'-difluoro-2'-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response.

Authors:  A W Blackstock; H Lightfoot; L D Case; J E Tepper; S K Mukherji; B S Mitchell; S G Swarts; S M Hess
Journal:  Clin Cancer Res       Date:  2001-10       Impact factor: 12.531

2.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

3.  Sonic hedgehog promotes desmoplasia in pancreatic cancer.

Authors:  Jennifer M Bailey; Benjamin J Swanson; Tomofumi Hamada; John P Eggers; Pankaj K Singh; Thomas Caffery; Michel M Ouellette; Michael A Hollingsworth
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

4.  High-resolution characterization of the pancreatic adenocarcinoma genome.

Authors:  Andrew J Aguirre; Cameron Brennan; Gerald Bailey; Raktim Sinha; Bin Feng; Christopher Leo; Yunyu Zhang; Jean Zhang; Joseph D Gans; Nabeel Bardeesy; Craig Cauwels; Carlos Cordon-Cardo; Mark S Redston; Ronald A DePinho; Lynda Chin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-15       Impact factor: 11.205

5.  Identification of pancreatic cancer stem cells.

Authors:  Chenwei Li; David G Heidt; Piero Dalerba; Charles F Burant; Lanjing Zhang; Volkan Adsay; Max Wicha; Michael F Clarke; Diane M Simeone
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

Review 6.  CCN proteins: multifunctional signalling regulators.

Authors:  Bernard Perbal
Journal:  Lancet       Date:  2004-01-03       Impact factor: 79.321

7.  CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family.

Authors:  Cristiane G Lin; Shr-Jeng Leu; Ningyu Chen; Christopher M Tebeau; Shao-Xia Lin; Cho-Yau Yeung; Lester F Lau
Journal:  J Biol Chem       Date:  2003-04-13       Impact factor: 5.157

8.  Measurement of multiple drug resistance transporter activity in putative cancer stem/progenitor cells.

Authors:  Vera S Donnenberg; E Michael Meyer; Albert D Donnenberg
Journal:  Methods Mol Biol       Date:  2009

9.  Chromosome abnormalities in pancreatic adenocarcinoma.

Authors:  C A Griffin; R H Hruban; P P Long; L A Morsberger; F Douna-Issa; C J Yeo
Journal:  Genes Chromosomes Cancer       Date:  1994-02       Impact factor: 5.006

10.  Development of an orthotopic human pancreatic cancer xenograft model using ultrasound guided injection of cells.

Authors:  Amanda Shanks Huynh; Dominique F Abrahams; Monica S Torres; Margaret K Baldwin; Robert J Gillies; David L Morse
Journal:  PLoS One       Date:  2011-05-27       Impact factor: 3.240

View more
  10 in total

Review 1.  Conjunction junction, what's the function? CCN proteins as targets in fibrosis and cancers.

Authors:  Andrew Leask
Journal:  Am J Physiol Cell Physiol       Date:  2020-03-04       Impact factor: 4.249

Review 2.  Protein PEGylation for cancer therapy: bench to bedside.

Authors:  Vijayalaxmi Gupta; Sneha Bhavanasi; Mohiuddin Quadir; Kevin Singh; Gaurav Ghosh; Kritin Vasamreddy; Arnab Ghosh; Teruna J Siahaan; Snigdha Banerjee; Sushanta K Banerjee
Journal:  J Cell Commun Signal       Date:  2018-11-29       Impact factor: 5.782

Review 3.  The role of CCNs in controlling cellular communication in the tumor microenvironment.

Authors:  Lauren B Birkeness; Snigdha Banerjee; Mohiuddin Quadir; Sushanta K Banerjee
Journal:  J Cell Commun Signal       Date:  2022-06-08       Impact factor: 5.908

Review 4.  An early history of CCN2/CTGF research: the road to CCN2 via hcs24, ctgf, ecogenin, and regenerin.

Authors:  Masaharu Takigawa
Journal:  J Cell Commun Signal       Date:  2017-10-26       Impact factor: 5.782

5.  The MAZ transcription factor is a downstream target of the oncoprotein Cyr61/CCN1 and promotes pancreatic cancer cell invasion via CRAF-ERK signaling.

Authors:  Gargi Maity; Inamul Haque; Arnab Ghosh; Gopal Dhar; Vijayalaxmi Gupta; Sandipto Sarkar; Imaan Azeem; Douglas McGregor; Abhishek Choudhary; Donald R Campbell; Suman Kambhampati; Sushanta K Banerjee; Snigdha Banerjee
Journal:  J Biol Chem       Date:  2018-02-06       Impact factor: 5.157

Review 6.  The CCN axis in cancer development and progression.

Authors:  Herman Yeger; Bernard Perbal
Journal:  J Cell Commun Signal       Date:  2021-04-20       Impact factor: 5.782

7.  CCN5/WISP-2 restores ER-∝ in normal and neoplastic breast cells and sensitizes triple negative breast cancer cells to tamoxifen.

Authors:  S Sarkar; A Ghosh; S Banerjee; G Maity; A Das; M A Larson; V Gupta; I Haque; O Tawfik; S K Banerjee
Journal:  Oncogenesis       Date:  2017-05-22       Impact factor: 7.485

8.  Identification and prognostic analysis of biomarkers to predict the progression of pancreatic cancer patients.

Authors:  Wei Li; Tiandong Li; Chenguang Sun; Yimeng Du; Linna Chen; Chunyan Du; Jianxiang Shi; Weijie Wang
Journal:  Mol Med       Date:  2022-04-15       Impact factor: 6.376

9.  Leptin-induced ER-α-positive breast cancer cell viability and migration is mediated by suppressing CCN5-signaling via activating JAK/AKT/STAT-pathway.

Authors:  Inamul Haque; Arnab Ghosh; Seth Acup; Snigdha Banerjee; Kakali Dhar; Amitabha Ray; Sandipto Sarkar; Suman Kambhampati; Sushanta K Banerjee
Journal:  BMC Cancer       Date:  2018-01-25       Impact factor: 4.430

10.  CCN-Based Therapeutic Peptides Modify Pancreatic Ductal Adenocarcinoma Microenvironment and Decrease Tumor Growth in Combination with Chemotherapy.

Authors:  Andrea Resovi; Patrizia Borsotti; Tommaso Ceruti; Alice Passoni; Massimo Zucchetti; Alexander Berndt; Bruce L Riser; Giulia Taraboletti; Dorina Belotti
Journal:  Cells       Date:  2020-04-13       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.